


What is claimed is:


1. A compound of Formula (I) represented by the structure:



Formula (I)


wherein:

- 10  $R_1$  is a moiety



$R_2$  is a moiety

15



$n$  is an integer of 1 and 3 to 9;

- 20  $m$  is an integer of 0 or 2;

$R_3$  and  $R_4$  are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethoxy, phenoxy optionally mono or di-substituted, and benzyloxy optionally mono or di-substituted;

25

R<sub>5</sub>, and R<sub>6</sub>, are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, halogen, nitro, phenyl optionally mono or di-substituted, phenoxy optionally mono or di-substituted, trifluoromethyl, trifluoromethoxy, and  
5 methanesulphonyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R<sub>1</sub> is 4-methoxyphenyl and R<sub>2</sub> is 4-  
10 chlorophenyl or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 wherein n is 3 and m is 2 or a pharmaceutically acceptable salt thereof.

15 4. The compound according to claim 1, 3-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(4-methoxybenzenesulfonyl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

20 5. The compound according to claim 1, 13-[3-(4-Chlorophenyl)prop-2-ynyl]-3-(4-methylbenzenesulfonyl)-pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising an effective amount of a compound of Claim 1 in combination with one or more pharmaceutically acceptable carriers.

25


7. A pharmaceutical composition according to claim 6 wherein R<sub>1</sub> is 4-methoxyphenyl and R<sub>2</sub> is 4-chlorophenyl or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to claim 6 wherein n is 3 and m is 2 or a  
30 pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition according to claim 6, where the compound is 3-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(4-methoxybenzenesulfonyl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

5 10. A pharmaceutical composition according to claim 6, where the compound is 13-[3-(4-Chlorophenyl)prop-2-ynyl]-3-(4-methylbenzenesulfonyl)-pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.


11. A method of treating, inhibiting or controlling a ras-associated disease by  
 10 inhibiting farnesyl-protein transferase(FPTase) enzyme in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I)




Formula (I)

wherein:

$R_1$  is a moiety



$R_2$  is a moiety



n is an integer of 1 and 3 to 9;

m is an integer of 0 or 2;

- 5      $R_3$  and  $R_4$  are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethoxy, phenoxy optionally mono or di substituted, and benzyloxy optionally mono or di substituted;
- 10     $R_5$ , and  $R_6$ , are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, halogen, nitro, phenyl optionally mono or di-substituted, phenoxy optionally mono or di-substituted, trifluoromethyl, trifluoromethoxy, and methanesulphonyl;
- 15    or a pharmaceutically acceptable salt thereof.

12. The method according to claim 11 wherein  $R_1$  is 4-methoxyphenyl and  $R_2$  is 4-chlorophenyl or a pharmaceutically acceptable salt thereof.

- 20    13. The method according to claim 11 wherein n is 3 and m is 2 or a pharmaceutically acceptable salt thereof.

- 25    14. The method according to claim 11, where the compound is 3-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(4-methoxybenzenesulfonyl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

- 30    15. The method according to claim 11, where the compound is 13-[3-(4-Chlorophenyl)prop-2-ynyl]-3-(4-methylbenzenesulfonyl)-pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

16. The method of Claim 11 wherein the ras-associated disease in mammals is selected from the group consisting of cancers of the pancreas, breast, lung, colon, epidermis, prostate, bladder, thyroid, myelodysplastic tumors and myeloid leukemia.


17. The method of Claim 11 wherein the ras-associated disease in mammals is selected from metastasis, suppressing angiogenesis, and inducing apoptosis.

5 18. The method of Claim 11 wherein the ras-associated proliferative disease in mammals is restenosis, neurofibromatosis, endometriosis, and psoriasis.

19. The method of Claim 11 wherein the ras-associated disease in mammals is prenyl modifications or proteins.

10

20. A process for the preparation of a compound of Formula (I).




Formula (I)

15


wherein:

R<sub>1</sub> is a moiety



20

R<sub>2</sub> is a moiety



25

n is an integer of 1 and 3-9;

m is an integer of 0 or 2;

5 R<sub>3</sub> and R<sub>4</sub> are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethoxy, phenoxy optionally mono or di substituted, and benzyloxy optionally mono or di substituted;


10 R<sub>5</sub>, and R<sub>6</sub>, are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, halogen, nitro, phenyl optionally mono or di-substituted, phenoxy optionally mono or di-substituted, trifluoromethyl, trifluoromethoxy, and methanesulphonyl.

or a pharmaceutically acceptable salt thereof,

15


which comprises

reacting a compound of the formula



20

with an alkyne of the formula



25

wherein LG is a leaving group

in the presence of a base to give a compound of Formula (I)

or a pharmaceutically acceptable salt thereof.

21. The process according to Claim 20 wherein the base is selected from alkali metal hydrides, alkali metal alkyls and alkali metal amide bases.

5 22. The process according to Claim 21 where the alkali metal hydride is sodium hydride.

23. The process according to Claim 21 wherein the alkali metal alkyl is butyl lithium.

10 24. The process according to Claim 21 wherein the alkali metal amide base is selected from lithium diisopropylamide and lithium bis(trimethylsilyl)amide.

25. The process according to Claim 20 wherein the leaving group is p-toluenesulfonyloxy, iodo or bromo.

15

20

25

30